Neurobionplus
Home About Journal AHEAD OF PRINT Current Issue Back Issues Instructions Submission Search Subscribe Blog    
Login 

Users Online: 509 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
SYMPOSIUM - MUSCULOSKELETAL ONCOLOGY
Year : 2018  |  Volume : 52  |  Issue : 1  |  Page : 58-64

Methotrexate free chemotherapy and limb salvage surgery for paediatric osteosarcoma in India


1 Division of Pediatric Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, India
2 Regional Cancer Center, Thiruvananthapuram, Kerala, India

Correspondence Address:
Dr. Reghu Kesavapillai Sukumaran
Pediatric Oncology, Aster Medcity, Kochi, Thiruvananthapuram, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ortho.IJOrtho_195_17

Rights and Permissions

Background: Osteosarcoma (OS) is the most common primary malignant tumor of bone. The survival of OS patients has steadily improved from<20% in the early 20th century to around 70% with current treatment. There are very few studies in pediatric OS from India analyzing various aspects of the disease. This study focuses on the clinical profile, treatment options, and their complications and survival outcomes in pediatric osteosarcoma(OS) patients. Materials and Methods: This was a retrospective observational study which included pediatric patients<14years of age, with newly diagnosed OS confirmed by histological diagnosis. Medical records of all patients were reviewed for clinical profile, treatment data, surgical management, and treatment complications. Patients alive at the end of treatment were followed up and overall(OAS) and disease-free survival(DFS) were analyzed. Results: Sixty-two patients were diagnosed with OS during the study of whom 55 opted for treatment. Cisplatin, adriamycin, and ifosfamide(PAI) was offered as chemotherapy and was completed as planned in the majority of patients. Limb salvage surgery was performed in most patients(87%, n=40). The local recurrence occurred in 7patients. The 3years overall survival for the cohort was 54.6% ± 7.8% and DFS was 43.4% ± 7.9%, with females and those with the localized disease having a significantly better DFS. Conclusions: High dose methotrexate free chemotherapy can give good OAS in localized disease and LSS is feasible in most of the pediatric OS patients. However the modest DFS even for localized disease with PAI chemotherapy and extremely poor outcomes in the metastatic OS, demand further research and innovations in systemic therapy to improve outcomes.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2668    
    Printed14    
    Emailed0    
    PDF Downloaded84    
    Comments [Add]    

Recommend this journal